---
schema_version: "secwatch.filing_event.v1"
accession: "0001000694-24-000040"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:28:36.819014+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Novavax Q3 revenue $85M, net loss $121M; FDA lifts clinical hold on combo vaccine

## Summary
- Total revenue $85M (down from $187M YoY); net loss $121M vs $131M; cash $924M as of Sept 30.
- FDA removed clinical hold on COVID-19-influenza combination and stand-alone influenza IND candidates.
- Full-year 2024 revenue guidance cut to $650-700M from $700-800M; product sales now $175-225M.
- Combined R&D/SG&A spend on track; targeting ~$500M in 2025 and ~$350M in 2026.

## SEC filing metadata
- accession: 0001000694-24-000040
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000100069424000040/0001000694-24-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000100069424000040/nvax-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001000694-24-000040
- JSON: https://secwatch.observer/filing/0001000694-24-000040.json
- Plain text: https://secwatch.observer/filing/0001000694-24-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.